Integra Lifesciences
IART
13.00
0.00
0.00%
Integra Lifesciences
US · IART
#3240 by market cap
13.00
0.00
0.00%
Live - 5344 symbols - heartbeat 465s ago
· 2026-10-08 10:11
Pre-market
13.02
+0.15%
After-hours
13.00
0.00%
- Market cap
- 1.01B
- P/E (TTM)i
- -144.44
- P/Bi
- 0.97
- EPSi
- -6.74
- Div yieldi
- 0.00%
- 52W posi
- 36%
Reader sentiment
Are you bullish or bearish on IART?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.11, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +1.53% YoY
Margins
- Gross margin
- 50.86%
- Operating margin
- 1.10%
- Net margin
- -31.58%
Key ratios & quality
- Enterprise valuei
- 2.62B
- Altman Z-Scorei
- 1.11
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.47B | 1.52B | 1.37B | 1.54B | 1.56B | 1.54B | 1.61B | 1.64B |
| Gross profit | 900.95M | 952.88M | 851.03M | 944.64M | 970.31M | 884.74M | 882.06M | 831.62M |
| Selling & admin expenses | 690.75M | 687.60M | 594.53M | 637.45M | 616.32M | 656.64M | 716.98M | 699.70M |
| Research & development | 78.04M | 79.57M | 77.38M | 93.05M | 101.19M | 104.19M | 115.38M | 98.97M |
| Operating profit | 111.00M | 158.68M | 151.37M | 197.23M | 238.92M | 111.53M | 28.41M | 18.00M |
| Pretax profit | 57.40M | 60.10M | 93.52M | 214.68M | 213.89M | 81.07M | -18.24M | -563.50M |
| Tax | -3.40M | 9.90M | -40.37M | 45.60M | 33.34M | 13.33M | -11.29M | -47.03M |
| Net profit | 60.80M | 50.20M | 133.89M | 169.08M | 180.55M | 67.74M | -6.94M | -516.47M |
| Basic EPS | 1 | 1 | 2 | 2 | 2 | 1 | 0 | -7 |
| Diluted EPS | 0.72 | 0.58 | 1.57 | 1.98 | 2.16 | 0.84 | -0.09 | -6.74 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 382.65M | 415.61M | 402.06M | 434.93M | 391.92M | 418.76M |
| Gross profit | 194.43M | 209.33M | 206.99M | 220.87M | 216.98M | 219.74M |
| Selling & admin expenses | 181.50M | 179.89M | 169.05M | 169.27M | 178.24M | 172.44M |
| Research & development | 24.73M | 27.00M | 22.46M | 24.79M | 23.50M | 24.25M |
| Operating profit | -15.50M | -1.31M | 11.76M | 23.04M | 11.47M | 19.29M |
| Pretax profit | -30.04M | -530.95M | -6.82M | 4.31M | -2.41M | 4.74M |
| Tax | -4.74M | -46.88M | -1.42M | 6.01M | 2.21M | 262.00K |
| Net profit | -25.29M | -484.07M | -5.40M | -1.70M | -4.62M | 4.48M |
| Basic EPS | 0 | -6 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.33 | -6.31 | -0.07 | -0.02 | -0.06 | 0.06 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 775.08M | 858.17M | 1.24B | 1.15B | 1.16B | 1.06B | 1.08B | 1.16B |
| Cash & ST investments | 138.84M | 198.91M | 470.17M | 513.45M | 456.66M | 309.10M | 273.57M | 263.74M |
| Inventory | 280.35M | 316.05M | 310.12M | 317.39M | 324.58M | 389.61M | 429.09M | 492.74M |
| Total assets | 3.11B | 3.30B | 3.62B | 3.78B | 3.89B | 3.78B | 4.04B | 3.60B |
| Total current liabilities | 262.55M | 331.31M | 401.01M | 340.02M | 320.91M | 306.98M | 922.13M | 455.98M |
| Short-term debt | 22.50M | 57.25M | 159.07M | 59.78M | 52.75M | 29.82M | 621.62M | 140.57M |
| Long-term debt | 1.33B | 1.30B | 1.41B | 1.50B | 1.41B | 1.49B | 1.20B | 1.73B |
| Total liabilities | 1,732,091,000.00 | 1,886,504,000.00 | 2,100,269,000.00 | 2,097,579,000.00 | 2,085,355,000.00 | 2,194,104,000.00 | 2,492,144,000.00 | 2,558,538,000.00 |
| Total equity | 1.38B | 1.42B | 1.51B | 1.68B | 1.80B | 1.59B | 1.55B | 1.04B |
| Retained earnings | 348.37M | 398.57M | 532.27M | 698.57M | 879.12M | 946.86M | 939.92M | 423.44M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.11B | 1.14B | 1.14B | 1.16B | 1.17B | 1.19B |
| Cash & ST investments | 273.30M | 253.61M | 267.88M | 263.74M | 265.50M | 274.08M |
| Inventory | 445.42M | 465.13M | 489.11M | 492.74M | 495.04M | 492.01M |
| Total assets | 4.05B | 3.67B | 3.65B | 3.60B | 3.58B | 3.56B |
| Total current liabilities | 918.45M | 929.81M | 364.05M | 455.98M | 346.85M | 330.88M |
| Short-term debt | 626.82M | 627.55M | 52.58M | 140.57M | 52.68M | 57.51M |
| Long-term debt | 1.23B | 1.23B | 1.79B | 1.73B | 1.83B | 1.83B |
| Total liabilities | 2,528,612,000.00 | 2,629,244,000.00 | 2,608,878,000.00 | 2,558,538,000.00 | 2,535,320,000.00 | 2,520,113,000.00 |
| Total equity | 1.52B | 1.04B | 1.04B | 1.04B | 1.04B | 1.04B |
| Retained earnings | 914.62M | 430.55M | 425.15M | 423.44M | 418.82M | 423.31M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 199.68M | 231.43M | 203.83M | 312.43M | 264.47M | 139.96M | 129.38M | 50.38M |
| Depreciation & amortization | 110.73M | 109.46M | 116.03M | 119.84M | 118.30M | 123.51M | 140.89M | 151.83M |
| Free cash flow | 121.94M | 96.90M | 139.94M | 264.35M | 217.38M | 73.09M | 15.01M | -45.25M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 349.59M | 0 | -100.00M | 0 | -125.00M | -275.00M | -52.47M | -221.00K |
| Ending cash balance | 138.84M | 198.91M | 470.17M | 513.45M | 456.66M | 276.40M | 246.38M | 235.05M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -11.26M | 8.92M | 40.91M | 11.82M | 9.80M | 22.80M |
| Depreciation & amortization | 37.19M | 37.69M | 38.52M | 38.43M | 38.43M | 38.14M |
| Free cash flow | -40.18M | -11.23M | 25.75M | -19.60M | -5.05M | 10.50M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | 0 | -- | -- |
| Ending cash balance | 239.10M | 217.91M | 232.19M | 235.05M | 236.81M | 214.42M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 5.20 | 3.60 | 9.13 | 10.57 | 10.35 | 3.99 | -0.44 | -39.90 |
| ROA %i | 1.92 | 1.57 | 3.87 | 4.57 | 4.71 | 1.77 | -0.18 | -13.52 |
| ROIC %i | 3.83 | 3.08 | 5.93 | 6.25 | 6.29 | 2.88 | 0.97 | -13.75 |
| 5-year avg ROE %i | 5.25 | 4.97 | 6.90 | 7.14 | 7.77 | 7.53 | 6.72 | -3.09 |
| EBIT margin %i | 8.29 | 7.52 | 12.03 | 17.19 | 16.92 | 8.59 | 3.25 | -29.19 |
| FCF / sales %i | 8.28 | 6.39 | 10.20 | 17.14 | 13.96 | 4.74 | 0.93 | -- |
| Current ratioi | 2.95 | 2.59 | 3.09 | 3.39 | 3.62 | 3.45 | 1.17 | 2.54 |
| Quick ratioi | 1.54 | 1.43 | 1.73 | 2.19 | 2.24 | 1.85 | 0.59 | 1.19 |
| Debt / assetsi | 43.57 | 44.13 | 45.79 | 43.66 | 41.53 | 44.47 | 49.15 | 56.45 |
| LT debt / equityi | 96.80 | 98.86 | 98.78 | 94.46 | 86.60 | 104.03 | 88.20 | 181.38 |
| Interest coveragei | 1.89 | 2.11 | 2.31 | 5.26 | 5.31 | 2.58 | 0.74 | -5.53 |
| Revenue CAGR (3Y) %i | 18.60 | 15.22 | 4.91 | 1.56 | 0.87 | 3.96 | 1.45 | 1.63 |
| Net income CAGR (3Y) %i | -- | -12.35 | 27.41 | 40.62 | 53.21 | -20.32 | -- | -- |
| FCF CAGR (3Y) %i | 19.51 | 11.94 | 25.36 | 29.42 | 30.91 | -19.47 | -61.56 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -1.85 | -38.92 | -38.71 | -39.90 | -38.64 | -0.70 |
| ROA %i | -0.71 | -12.93 | -12.85 | -13.52 | -13.00 | -0.20 |
| ROIC %i | 0.25 | -13.57 | -13.38 | -13.75 | -12.96 | 1.21 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 2.02 | -29.63 | -28.22 | -29.19 | -27.12 | 5.56 |
| FCF / sales %i | -- | -- | -- | -- | -- | 0.70 |
| Current ratioi | 1.21 | 1.23 | 3.14 | 2.54 | 3.38 | 3.60 |
| Quick ratioi | 0.57 | 0.58 | 1.46 | 1.19 | 1.53 | 1.64 |
| Debt / assetsi | 49.82 | 54.90 | 55.01 | 56.45 | 57.00 | 57.50 |
| LT debt / equityi | 91.34 | 133.46 | 188.25 | 181.38 | 190.59 | 190.86 |
| Interest coveragei | 0.43 | -6.14 | -5.69 | -5.53 | -4.96 | 1.00 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Specialty Surgery is the largest reported line at 73.85% of revenue, across 2 reported segments.
- The next-largest line, Tissue Reconstruction, is a distant second at 26.15% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Specialty Surgery73.85%
Tissue Reconstruction26.15%
Quote time 2026-10-08 10:11:00 · For reference only, not investment advice and not tailored to your situation.